Arbutus Biopharma (ABUS) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ABUS Stock Forecast

Arbutus Biopharma stock forecast is as follows: an average price target of $8.50 (represents a 143.55% upside from ABUS’s last price of $3.49) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.

ABUS Price Target

The average price target for Arbutus Biopharma (ABUS) is $8.50 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $8.50 to $8.50. This represents a potential 143.55% upside from ABUS's last price of $3.49.

ABUS Analyst Ratings

Buy

According to 3 Wall Street analysts, Arbutus Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for ABUS stock is 0 'Strong Buy' (0.00%), 3 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Arbutus Biopharma Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Mar 17, 2022	Ed Arce	H.C. Wainwright	$8.50	$3.02	181.46%	143.55%

Row per page

Go to

The latest Arbutus Biopharma stock forecast, released on Mar 17, 2022 by Ed Arce from H.C. Wainwright, set a price target of $8.50, which represents a 181.46% increase from the stock price at the time of the forecast ($3.02), and a 143.55% increase from ABUS last price ($3.49).

Arbutus Biopharma Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	-
Avg Price Target	-	-	-
Last Closing Price	$3.49	$3.49	$3.49
Upside/Downside	-100.00%	-100.00%	-100.00%

In the current month, the average price target of Arbutus Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Arbutus Biopharma's last price of $3.49. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Sep 05, 2024	Jefferies	Buy	Buy	Hold
Jun 28, 2022	JMP Securities	Market Outperform	Market Outperform	Hold
Mar 17, 2022	H.C. Wainwright	Buy	Buy	Hold
Feb 02, 2022	Jefferies	-	Buy	Upgrade

Row per page

Go to

Arbutus Biopharma's last stock rating was published by Jefferies on Sep 05, 2024. The company gave ABUS a "Buy" rating, the same as its previous rate.

Arbutus Biopharma Financial Forecast

Arbutus Biopharma Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	$2.15M	$4.66M	$4.65M	$6.69M	$6.25M	$5.95M	$14.24M	$12.58M	$3.21M	$3.34M	$2.33M	$2.11M	$2.39M	$1.52M	$1.51M	$1.49M	$1.62M	$3.06M	$653.00K	$679.00K	$1.44M	$235.00K
Avg Forecast	$1.36M	$1.36M	$1.38M	$1.41M	$1.59M	$1.86M	$1.77M	$2.71M	$4.78M	$4.75M	$6.18M	$6.04M	$6.18M	$9.37M	$6.77M	$4.37M	$2.88M	$2.39M	$2.12M	$3.30M	$2.03M	$1.70M	$1.80M	$1.30M	$1.42M	$5.28M	$786.75K	$1.24M	$1.56M	$269.56K
High Forecast	$1.57M	$1.57M	$1.60M	$1.47M	$1.64M	$1.86M	$1.77M	$2.71M	$4.82M	$4.75M	$7.14M	$6.98M	$7.14M	$9.37M	$6.77M	$4.37M	$2.88M	$2.39M	$2.12M	$3.30M	$2.03M	$1.70M	$1.80M	$1.30M	$1.42M	$5.28M	$786.75K	$1.24M	$1.87M	$323.47K
Low Forecast	$1.23M	$1.23M	$1.25M	$1.35M	$1.54M	$1.86M	$1.77M	$2.71M	$4.74M	$4.75M	$5.59M	$5.47M	$5.59M	$9.37M	$6.77M	$4.37M	$2.88M	$2.39M	$2.12M	$3.30M	$2.03M	$1.70M	$1.80M	$1.30M	$1.42M	$5.28M	$786.75K	$1.24M	$1.24M	$215.65K
# Analysts	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4	3	7	9	17
Surprise %	-	-	-	-	-	-	-	-	0.45%	0.98%	0.75%	1.11%	1.01%	0.63%	2.10%	2.88%	1.11%	1.40%	1.10%	0.64%	1.17%	0.89%	0.84%	1.15%	1.14%	0.58%	0.83%	0.55%	0.92%	0.87%

Arbutus Biopharma's average Quarter revenue forecast for Mar 24 based on 1 analysts is $2.71M, with a low forecast of $2.71M, and a high forecast of $2.71M. ABUS's average Quarter revenue forecast represents a 26.54% increase compared to the company's last Quarter revenue of $2.15M (Dec 23).

Arbutus Biopharma EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4	3	7	9	17
EBITDA	-	-	-	-	-	-	-	-	$-20.52M	$-21.56M	$-18.39M	$-15.87M	$-20.01M	$-16.56M	$-13.12M	$-10.22M	$-20.33M	$-17.95M	$-18.19M	$-15.17M	$-15.76M	$-17.19M	$-12.49M	$-12.32M	$-23.15M	$-93.55M	$-22.81M	$-22.73M	$-16.72M	$-18.25M
Avg Forecast	$-1.36M	$-1.36M	$-1.38M	$-1.41M	$-1.59M	$-1.86M	$-1.77M	$-2.71M	$-4.78M	$-4.75M	$-6.18M	$-6.04M	$-6.18M	$-9.37M	$-6.77M	$-14.19M	$-2.88M	$-2.39M	$-2.12M	$-16.48M	$-2.03M	$-1.70M	$-1.80M	$-14.70M	$-1.42M	$-5.28M	$-786.75K	$-13.28M	$-18.01M	$-20.59M
High Forecast	$-1.23M	$-1.23M	$-1.25M	$-1.35M	$-1.54M	$-1.86M	$-1.77M	$-2.71M	$-4.74M	$-4.75M	$-5.59M	$-5.47M	$-5.59M	$-9.37M	$-6.77M	$-11.36M	$-2.88M	$-2.39M	$-2.12M	$-13.19M	$-2.03M	$-1.70M	$-1.80M	$-11.76M	$-1.42M	$-5.28M	$-786.75K	$-10.63M	$-14.41M	$-16.47M
Low Forecast	$-1.57M	$-1.57M	$-1.60M	$-1.47M	$-1.64M	$-1.86M	$-1.77M	$-2.71M	$-4.82M	$-4.75M	$-7.14M	$-6.98M	$-7.14M	$-9.37M	$-6.77M	$-17.03M	$-2.88M	$-2.39M	$-2.12M	$-19.78M	$-2.03M	$-1.70M	$-1.80M	$-17.65M	$-1.42M	$-5.28M	$-786.75K	$-15.94M	$-21.61M	$-24.71M
Surprise %	-	-	-	-	-	-	-	-	4.29%	4.54%	2.98%	2.63%	3.24%	1.77%	1.94%	0.72%	7.05%	7.51%	8.59%	0.92%	7.75%	10.09%	6.95%	0.84%	16.29%	17.73%	28.99%	1.71%	0.93%	0.89%

undefined analysts predict ABUS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Arbutus Biopharma's previous annual EBITDA (undefined) of $NaN.

Arbutus Biopharma Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4	3	7	9	17
Net Income	-	-	-	-	-	-	-	-	$-19.31M	$-20.10M	$-17.09M	$-15.46M	$-22.91M	$-17.32M	$-14.28M	$-15.77M	$-21.88M	$-19.16M	$-19.39M	$-16.38M	$-17.04M	$-18.75M	$-14.09M	$-13.86M	$-24.65M	$-82.50M	$-23.32M	$-23.25M	$-17.43M	$-18.63M
Avg Forecast	$-16.54M	$-16.06M	$-15.12M	$-15.12M	$-15.12M	$-17.77M	$-18.14M	$-20.79M	$-19.66M	$-21.17M	$-21.17M	$-25.70M	$-25.33M	$-24.07M	$-23.32M	$-20.69M	$-35.73M	$-44.75M	$-42.31M	$-17.81M	$-41.64M	$-40.62M	$-45.13M	$-16.54M	$-68.07M	$-49.83M	$-70.05M	$-13.59M	$-18.77M	$-21.02M
High Forecast	$-14.50M	$-14.09M	$-13.26M	$-11.76M	$-13.23M	$-15.58M	$-15.91M	$-18.23M	$-19.22M	$-18.56M	$-18.56M	$-22.54M	$-22.21M	$-24.07M	$-23.32M	$-16.55M	$-35.73M	$-44.75M	$-42.31M	$-14.24M	$-41.64M	$-40.62M	$-45.13M	$-13.24M	$-68.07M	$-49.83M	$-70.05M	$-10.87M	$-15.02M	$-16.81M
Low Forecast	$-19.89M	$-19.32M	$-18.18M	$-16.80M	$-17.01M	$-21.36M	$-21.82M	$-25.00M	$-20.10M	$-25.45M	$-25.45M	$-30.91M	$-30.45M	$-24.07M	$-23.32M	$-24.83M	$-35.73M	$-44.75M	$-42.31M	$-21.37M	$-41.64M	$-40.62M	$-45.13M	$-19.85M	$-68.07M	$-49.83M	$-70.05M	$-16.30M	$-22.52M	$-25.22M
Surprise %	-	-	-	-	-	-	-	-	0.98%	0.95%	0.81%	0.60%	0.90%	0.72%	0.61%	0.76%	0.61%	0.43%	0.46%	0.92%	0.41%	0.46%	0.31%	0.84%	0.36%	1.66%	0.33%	1.71%	0.93%	0.89%

Arbutus Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ABUS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Arbutus Biopharma SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4	3	7	9	17
SG&A	-	-	-	-	-	-	-	-	$5.10M	$5.84M	$5.98M	$5.55M	$4.25M	$3.49M	$5.20M	$4.89M	$4.70M	$4.15M	$4.45M	$3.85M	$3.54M	$4.07M	$3.57M	$3.55M	$1.88M	$3.25M	$8.19M	$4.41M	$3.67M	$4.33M
Avg Forecast	$2.27M	$2.27M	$2.31M	$2.35M	$2.65M	$3.10M	$2.94M	$4.52M	$7.98M	$7.92M	$10.30M	$10.06M	$10.29M	$15.48M	$11.18M	$7.21M	$4.76M	$3.95M	$3.50M	$5.46M	$3.36M	$2.81M	$2.97M	$2.15M	$2.35M	$8.71M	$1.30M	$2.04M	$2.57M	$445.14K
High Forecast	$2.62M	$2.62M	$2.67M	$2.45M	$2.73M	$3.10M	$2.94M	$4.52M	$8.03M	$7.92M	$11.90M	$11.63M	$11.90M	$15.48M	$11.18M	$7.21M	$4.76M	$3.95M	$3.50M	$5.46M	$3.36M	$2.81M	$2.97M	$2.15M	$2.35M	$8.71M	$1.30M	$2.04M	$3.08M	$534.16K
Low Forecast	$2.05M	$2.05M	$2.09M	$2.25M	$2.57M	$3.10M	$2.94M	$4.52M	$7.91M	$7.92M	$9.32M	$9.11M	$9.32M	$15.48M	$11.18M	$7.21M	$4.76M	$3.95M	$3.50M	$5.46M	$3.36M	$2.81M	$2.97M	$2.15M	$2.35M	$8.71M	$1.30M	$2.04M	$2.06M	$356.11K
Surprise %	-	-	-	-	-	-	-	-	0.64%	0.74%	0.58%	0.55%	0.41%	0.23%	0.47%	0.68%	0.99%	1.05%	1.27%	0.71%	1.05%	1.45%	1.20%	1.66%	0.80%	0.37%	6.30%	2.16%	1.43%	9.72%

Arbutus Biopharma's average Quarter SG&A projection for Mar 24 is $4.52M, based on 1 Wall Street analysts, with a range of $4.52M to $4.52M. The forecast indicates a -11.31% fall compared to ABUS last annual SG&A of $5.10M (Dec 23).

Arbutus Biopharma EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	3	3	1	1	1	3	1	1	1	1	1	1	1	1	1	1	1	4	6	4	4	7	4	3	7	9	17
EPS	-	-	-	-	-	-	-	-	$-0.11	$-0.12	$-0.00	$-0.10	$-0.15	$-0.11	$-0.10	$-0.11	$-0.22	$-0.24	$-0.23	$-0.21	$-0.18	$-0.27	$-0.25	$-0.25	$-0.36	$-1.50	$-0.46	$-0.47	$-0.36	$-0.34
Avg Forecast	$-0.09	$-0.09	$-0.08	$-0.08	$-0.08	$-0.09	$-0.10	$-0.11	$-0.10	$-0.11	$-0.11	$-0.14	$-0.13	$-0.13	$-0.12	$-0.16	$-0.19	$-0.24	$-0.23	$-0.23	$-0.22	$-0.22	$-0.24	$-0.31	$-0.36	$-0.27	$-0.37	$-0.32	$-0.42	$-0.44
High Forecast	$-0.08	$-0.07	$-0.07	$-0.06	$-0.07	$-0.08	$-0.08	$-0.10	$-0.10	$-0.10	$-0.10	$-0.12	$-0.12	$-0.13	$-0.12	$-0.16	$-0.19	$-0.24	$-0.23	$-0.23	$-0.22	$-0.22	$-0.24	$-0.31	$-0.36	$-0.27	$-0.37	$-0.32	$-0.34	$-0.35
Low Forecast	$-0.11	$-0.10	$-0.10	$-0.09	$-0.09	$-0.11	$-0.12	$-0.13	$-0.11	$-0.13	$-0.13	$-0.16	$-0.16	$-0.13	$-0.12	$-0.16	$-0.19	$-0.24	$-0.23	$-0.23	$-0.22	$-0.22	$-0.24	$-0.31	$-0.36	$-0.27	$-0.37	$-0.32	$-0.50	$-0.53
Surprise %	-	-	-	-	-	-	-	-	1.06%	1.07%	0.00%	0.70%	1.12%	0.86%	0.77%	0.69%	1.16%	1.01%	1.02%	0.91%	0.82%	1.25%	1.04%	0.80%	1.01%	5.66%	1.23%	1.46%	0.86%	0.77%

According to undefined Wall Street analysts, Arbutus Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ABUS previous annual EPS of $NaN (undefined).

Arbutus Biopharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VBIV	VBI Vaccines	$0.07	$5.00	7042.86%	Strong Buy
ADAP	Adaptimmune Therapeutics	$0.67	$2.83	322.39%	Buy
AFMD	Affimed	$3.00	$7.50	150.00%	Buy
ABUS	Arbutus Biopharma	$3.49	$8.50	143.55%	Buy
CRVS	Corvus Pharmaceuticals	$8.40	$10.67	27.02%	Buy
ADMA	ADMA Biologics	$20.63	$16.00	-22.44%	Strong Buy

ABUS Forecast FAQ

Is Arbutus Biopharma a good buy?

Yes, according to 3 Wall Street analysts, Arbutus Biopharma (ABUS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 3 'Buy' recommendations, accounting for 100.00% of ABUS's total ratings.

What is ABUS's price target?

Arbutus Biopharma (ABUS) average price target is $8.5 with a range of $8.5 to $8.5, implying a 143.55% from its last price of $3.49. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Arbutus Biopharma stock go up soon?

According to Wall Street analysts' prediction for ABUS stock, the company can go up by 143.55% (from the last price of $3.49 to the average price target of $8.5), up by 143.55% based on the highest stock price target, and up by 143.55% based on the lowest stock price target.

Can Arbutus Biopharma stock reach $5?

ABUS's average twelve months analyst stock price target of $8.5 supports the claim that Arbutus Biopharma can reach $5 in the near future.

What are Arbutus Biopharma's analysts' financial forecasts?

Arbutus Biopharma's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $7.93M (high $7.98M, low $7.88M), average EBITDA is $-7.928M (high $-7.88M, low $-7.976M), average net income is $-71.819M (high $-62.946M, low $-85.189M), average SG&A $13.21M (high $13.29M, low $13.13M), and average EPS is $-0.38 (high $-0.333, low $-0.451). ABUS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $5.51M (high $6.22M, low $5.06M), average EBITDA is $-5.514M (high $-5.063M, low $-6.215M), average net income is $-62.842M (high $-53.605M, low $-74.184M), average SG&A $9.19M (high $10.36M, low $8.44M), and average EPS is $-0.333 (high $-0.284, low $-0.393).

Did the ABUS's actual financial results beat the analysts' financial forecasts?

Based on Arbutus Biopharma's last annual report (Dec 2023), the company's revenue was $18.14M, which missed the average analysts forecast of $21.75M by -16.59%. Apple's EBITDA was $-78.103M, beating the average prediction of $-21.75M by 259.10%. The company's net income was $-72.849M, missing the average estimation of $-87.698M by -16.93%. Apple's SG&A was $22.48M, missing the average forecast of $36.25M by -38.01%. Lastly, the company's EPS was $-0.0004, missing the average prediction of $-0.464 by -99.91%. In terms of the last quarterly report (Dec 2023), Arbutus Biopharma's revenue was $2.14M, missing the average analysts' forecast of $4.78M by -55.17%. The company's EBITDA was $-20.52M, beating the average prediction of $-4.785M by 328.86%. Arbutus Biopharma's net income was $-19.312M, missing the average estimation of $-19.659M by -1.77%. The company's SG&A was $5.1M, missing the average forecast of $7.98M by -36.04%. Lastly, the company's EPS was $-0.11, beating the average prediction of $-0.104 by 5.75%